BioMarin’s Voxzogo has been shown to increase growth rates in children with hypochondroplasia, a genetic cause of very short stature, in a phase 2 trial. Hypochondroplasia is a form of skeletal ...

BioMarin Pharmaceutical (Nasdaq: BMRN) reported $747.31 million in revenue for the fourth quarter, a 16% year-over-year increase. The San Rafael-based global producer of genetic treatments for ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), a biotechnology company specializing in therapies for rare genetic diseases with a market capitalization of $13.15 billion, has been navigating a ...

Oppenheimer upgrades BioMarin on long term outlook Amgen India opens with $200 million investment plan through 2025 National Grid sells $1.7 billion US renewables arm to Brookfield ...

BioMarin Pharmaceutical stock opened at $68.25 on Thursday. The company has a quick ratio of 2.62, a current ratio of 5.33 and a debt-to-equity ratio of 0.11. The firm has a 50-day moving average ...

Robert W. Baird lowered their target price on BioMarin Pharmaceutical from $72.00 to $65.00 and set a “neutral” rating on the stock in a report on Wednesday, October 30th.

A slimmed-down BioMarin started the new year with a bang, hitting the annual J.P. Morgan Healthcare Conference with the goal of tapping its skillset to strike deals that bolster its pipeline of ...

Both headline numbers obliterated analyst estimates. Collectively, pundits tracking BioMarin's stock were estimating the company would earn a bit over $711 million and post an adjusted net income ...